

Collaborative Working Project Executive Summary

July 2026
CP-594078

Optimising Disease Reassessment in Inflammatory Bowel Disease (IBD) Services

Project Title

A Collaborative Working Agreement between Maidstone and Tunbridge Wells NHS Trust and Johnson & Johnson Innovative Medicine UK to optimise disease reassessment in inflammatory bowel disease services.

Partner Organisations

- Maidstone and Tunbridge Wells NHS Trust, Maidstone Hospital, Hermitage Lane, Maidstone, Kent ME16 9QQ.
- Johnson & Johnson Innovative Medicine UK, 50-100 Holmers Farm Way, High Wycombe HP12 4EG.
- Clinical input will also include gastroenterology professionals from participating UK NHS IBD services, including project team members from St George's University Hospitals NHS Foundation Trust.

Project Rationale

National expectations for IBD care highlight the importance of timely disease reassessment, objective monitoring and treat-to-target care. Relevant guidance and standards, including GIRFT recommendations, IBD Standards, NICE guidance and STRIDE-II principles, provide a foundation for services to deliver consistent, proactive care for people living with IBD.

This project provides an opportunity for NHS partners and Johnson & Johnson Innovative Medicine UK to work collaboratively to identify where reassessment pathways can be optimised, share learning across services and co-develop practical, service-led recommendations that support quality improvement and pathway consistency.

The collaboration will map current reassessment practice across participating NHS IBD services, review aggregated, non-identifiable service-level information and compare findings with relevant national guidance and standards where appropriate. Findings will then be interpreted collaboratively, drawing on real-world clinical and operational experience, to explore drivers of variation and identify practical opportunities to optimise reassessment pathways.

Project Period

Expected start: July 2026. Expected completion: May 2027.

Project Objectives

- Assess variation in approaches to disease reassessment across different UK IBD services and compare this with relevant national standards where appropriate.
- Highlight gaps or inconsistencies in reassessment strategies and, through a collaborative workshop, identify quality improvement opportunities.
- Produce a shared final report summarising findings, workshop outputs and agreed recommendations.

Benefits

Patient specific

- Potential for more consistent disease reassessment pathways across participating IBD services.
- Service-led recommendations focused on pathway optimisation and patient-centred care.
- Shared learning to support high-quality, consistent IBD service delivery.

NHS specific

- Improved understanding of current reassessment practice and variation across UK IBD services.
- Support for benchmarking against relevant national standards and guidance where appropriate.
- Practical recommendations to inform quality improvement, pathway consistency and service standardisation.

Johnson & Johnson Innovative Medicine UK specific

- Opportunity to support a non-promotional collaborative working project focused on service improvement and shared healthcare challenges.
- Partnership with NHS clinical experts to support optimised pathways that enable clearer therapeutic decision-making in IBD care.

Resource Allocation

Party	Total hours	Total cost
Johnson & Johnson Innovative Medicine UK	210	£29,969.50 (£19,278 in funding additional statistical analysis, the rest of the funding is the hours of Johnson & Johnson's colleagues time)
NHS	300	£12,389.00
Overall total	510	£42,358.50

All data used within the project will be aggregated and non-identifiable. Johnson & Johnson Innovative Medicine UK will not have access to individual patient data.

Contact Details

- Johnson & Johnson Innovative Medicine UK: Dr Megan Walker, Therapy Area Director,
- Maidstone and Tunbridge Wells NHS Trust: Dr Sara Mumford, Chief Medical Officer